Comprehensive evaluation of the neuropeptide-Y gene variants in the risk of obesity: A case-control study and meta-Analysis

Pharmacogenetics and Genomics

Volumn 25, Issue 10, 2015, Pages 501-510

  Zain, Shamsul Mohd ^a,b   Mohamed, Zahurin ^a,b   Jalaludin, Muhammad Yazid ^b   Fauzi, Fatin ^a,b   Hamidi, Anahita ^a,b   Zaharan, Nur Lisa ^b  

^a Pharmacogenomics Laboratory   (Canada)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

BMI; genetic variation; neuropeptide Y; obesity; polymorphism; SNP

Indexed keywords

NEUROPEPTIDE Y; TRIACYLGLYCEROL;

ALLELE; ARTICLE; BODY FAT; BODY MASS; CASE CONTROL STUDY; CORRELATIONAL STUDY; EVALUATION STUDY; GENETIC VARIABILITY; HUMAN; OBESITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; WAIST CIRCUMFERENCE; DEMOGRAPHY; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; META ANALYSIS; PUBLISHING; RISK FACTOR;

CASE-CONTROL STUDIES; DEMOGRAPHY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEUROPEPTIDE Y; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS; RISK FACTORS;

EID: 84941965240     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000164     Document Type: Article

References (39)

1. Pampel FC, Krueger PM, Denney JT. Socioeconomic disparities in health behaviors. Annu Rev Sociol 2010; 36:349-370.
2. Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, Nathan DM, Schwartz MW, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? Diabetes Care 2011; 34:1424-1430.
3. Narkiewicz K. Obesity and hypertension-The issue is more complex than we thought. Nephrol Dial Transplant 2006; 21:264-267.
4. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: An update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113:898-918.
5. Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes, and cardiovascular risk in children: An American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 2003; 107:1448-1453.
6. Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. Am J Hum Genet 2012; 90:7-24.
7. Zaitlen N, Kraft P, Patterson N, Pasaniuc B, Bhatia G, Pollack S, Price AL. Using extended genealogy to estimate components of heritability for 23 quantitative and dichotomous traits. PLoS Genet 2013; 9:e1003520.
8. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature 2015; 518:197-206.
9. Kalra SP, Kalra PS. NPY and cohorts in regulating appetite, obesity and metabolic syndrome: beneficial effects of gene therapy. Neuropeptides 2004; 38:201-211.
10. Beck B. Neuropeptide Y in normal eating and in genetic and dietary-induced obesity. Philos Trans R Soc Lond B Biol Sci 2006; 361:1159-1185.
11. Sindelar DK, Palmiter RD, Woods SC, Schwartz MW. Attenuated feeding responses to circadian and palatability cues in mice lacking neuropeptide Y. Peptides 2005; 26:2597-2602.
12. Zain SM, Mohamed R, Cooper DN, Razali R, Rampal S, Mahadeva S, et al. Genome-wide analysis of copy number variation identifies candidate gene loci associated with the progression of non-Alcoholic fatty liver disease. PLoS One 2014; 9:e95604.
13. Van Rossum CT, Hoebee B, van Baak MA, Mars M, Saris WH, Seidell JC. Genetic variation in the leptin receptor gene, leptin, and weight gain in young Dutch adults. Obes Res 2003; 11:377-386.
14. Yeung EH, Zhang C, Chen J, Bowers K, Hu FB, Kang G, Qi L. Polymorphisms in the neuropeptide Y gene and the risk of obesity: findings from two prospective cohorts. J Clin Endocrinol Metab 2011; 96: E2055-E2062.
15. Jaakkola U, Kallio J, Heine RJ, Nijpels G, Hart LM, Maassen JA, et al. Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: The Hoorn Study. Eur J Clin Nutr 2009; 63:150-152.
16. Karvonen MK, Valkonen VP, Lakka TA, Salonen R, Koulu M, Pesonen U, et al. Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis 2001; 159:145-151.
17. Shah SH, Freedman NJ, Zhang L, Crosslin DR, Stone DH, Haynes C, et al. Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis. PLoS Genet 2009; 5:e1000318.
18. Tiwari AK, Brandl EJ, Weber C, Likhodi O, Zai CC, Hahn MK, et al. Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients. J Clin Psychopharmacol 2013; 33:11-17.
19. Parizadeh SA, Jamialahmadi K, Rooki H, Zaim-Kohan H, Mirhafez SR, Hosseini N, et al. Association of neuropeptide Ygene rs16147 polymorphism with metabolic syndrome in patients with documented coronary artery disease. Ann Hum Biol 2015; 42:178-183.
20. Kim NS, Oh SM, Ko MM, Cha MH, Kang BK, Bang OS. Association of the C-399T promoter polymorphism of neuropeptide Y with susceptibility to ischemic stroke. Clin Biochem 2009; 42:1699-1704.
21. Mutschler J, Abbruzzese E, von der Goltz C, Dinter C, Mobascher A, Thiele H, et al. Genetic variation in the neuropeptide Y gene promoter is associated with increased risk of tobacco smoking. Eur Addict Res 2012; 18:246-252.
22. Mutschler J, Abbruzzese E, Wiedemann K, von der Goltz C, Dinter C, Mobascher A, et al. Functional polymorphism in the neuropeptide Y gene promoter (rs16147) is associated with serum leptin levels and waist-hip ratio in women. Ann Nutr Metab 2013; 62:271-276.
23. Olza J, Gil-Campos M, Leis R, Rupérez AI, Tojo R, Cañete R, et al. Influence of variants in the NPY gene on obesity and metabolic syndrome features in Spanish children. Peptides 2013; 45:22-27.
24. Cole TJ, Lobstein T. Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. Pediatr Obes 2012; 7:284-294.
25. World Health Organization. Waist circumference and waist-hip ratio: report of a WHO expert consultation. Geneva: World Health Organization; 2008.
26. Poh BK, Jannah AN, Chong LK, Ruzita AT, Ismail MN, McCarthy D. Waist circumference percentile curves for Malaysian children and adolescents aged 6.0-16.9 years. Int J Pediatr Obes 2011; 6:229-235.
27. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-Analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6:e1000100.
28. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-Analyses. Eur J Epidemiol 2010; 25:603-605.
29. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-Analyses. BMJ 2003; 327:557-560.
30. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50:1088-1101.
31. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-Analysis detected by a simple, graphical test. BMJ 1997; 315:629-634.
32. Bhaskar LV, Thangaraj K, Pardhasaradhi G, Kumar KP, Singh L, Rao VR. Neuropeptide Y gene polymorphisms are not associated with obesity in a South Indian population. Eur J Clin Nutr 2010; 64:868-872.
33. Ding B, Kull B, Liu Z, Mottagui-Tabar S, Thonberg H, Gu HF, et al. Human neuropeptide Y signal peptide gain-of-function polymorphism is associated with increased body mass index: possible mode of function. Regul Pept 2005; 127:45-53.
34. Karvonen MK, Pesonen U, Koulu M, Niskanen L, Laakso M, Rissanen A, et al. Association of a leucine(7)-To-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med 1998; 4:1434-1437.
35. Mattevi VS, Zembrzuski VM, Hutz MH. Association analysis of genes involved in the leptin-signaling pathway with obesity in Brazil. Int J Obes Relat Metab Disord 2002; 26:1179-1185.
36. Zhou Z, Zhu G, Hariri AR, Enoch MA, Scott D, Sinha R, et al. Genetic variation in human NPY expression affects stress response and emotion. Nature 2008; 452:997-1001.
37. Hohmann S, Buchmann AF, Witt SH, Rietschel M, Jennen-Steinmetz C, Schmidt MH, et al. Increasing association between a neuropeptide Y promoter polymorphism and body mass index during the course of development. Pediatr Obes 2012; 7:453-460.
38. Walker E, Hernandez AV, Kattan MW. Meta-Analysis: Its strengths and limitations. Cleve Clin J Med 2008; 75:431-439.
39. Nordman S, Ding B, Ostenson CG, Kärvestedt L, Brismar K, Efendic S, Gu HF. Leu7Pro polymorphism in the neuropeptide Y (NPY) gene is associated with impaired glucose tolerance and type 2 diabetes in Swedish men. Exp Clin Endocrinol Diabetes 2005; 113:282-287.